Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab + IRX-2 in Oral/Oropharyngeal Cancer
NCT03575234Phase 1Withdrawn
- Sponsor
- Emory University
- Start
- Jul 2020
- Primary completion
- Jan 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of citoplurikin in oral cavity squamous cell carcinoma (OCSCC) and oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Emory University. Primary endpoints: Incidence of adverse events up to 4 years, Change in tumor size and 1 more. Planned start Jul 2020; status: withdrawn.
02
Drugs
citoplurikin
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03575234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575234.